Aigen Investment Management LP Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Aigen Investment Management LP purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 7,504 shares of the company's stock, valued at approximately $415,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of TARS. R Squared Ltd purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. FMR LLC grew its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after buying an additional 3,537 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at $223,000. Oppenheimer & Co. Inc. acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $227,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in Tarsus Pharmaceuticals in the 4th quarter worth $249,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS traded up $2.90 during mid-day trading on Friday, reaching $46.47. 625,250 shares of the stock were exchanged, compared to its average volume of 640,622. The company has a market capitalization of $1.78 billion, a P/E ratio of -12.20 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The business's 50 day moving average is $50.14 and its 200-day moving average is $43.61. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28.

Remove Ads

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TARS shares. Guggenheim reiterated a "buy" rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Barclays decreased their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group increased their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.